prednisolone has been researched along with Muscle Contraction in 48 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind trial of prednisolone in patients with rheumatoid arthritis using doses of zero, 3 mg and 5 mg is reported." | 9.04 | The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis. ( Chamberlain, MA; Keenan, J, 1976) |
| "A double-blind trial of prednisolone in patients with rheumatoid arthritis using doses of zero, 3 mg and 5 mg is reported." | 5.04 | The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis. ( Chamberlain, MA; Keenan, J, 1976) |
| " We investigated the effects of spironolactone, an unselective mineralocorticoid-receptor antagonist, on in vivo cardiac haemodynamics, cardiomyocyte damage and fibrosis in prednisolone treated Sgcd-null mice." | 3.76 | Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism. ( Bauer, R; Blain, A; Bushby, K; Greally, E; Lochmüller, H; MacGowan, GA; Straub, V, 2010) |
| " The clinical improvement after drug therapy (prednisolone and etretinate) correlated well with the measurable changes in vivo of several metabolites and indices important in muscle contraction, such as phosphocreatine (PCr), inorganic phosphate (P(i)), intramuscular pH and the phosphorylation potential (PCr/Pi)." | 3.68 | Altered muscle metabolism in pustular psoriasis (Zumbusch type): demonstration by 31P magnetic resonance spectroscopy. ( Altmeyer, P; Beyer, HK; el-Gammal, S; Kiricuta, IC, 1993) |
| "Using a new method for inducing IgE-mediated, systemic anaphylaxis in the rat both prednisolone and ketotifen had been shown previously to be effective in suppressing the bronchial anaphylaxis in vivo." | 3.67 | The effect of prednisolone and ketotifen on the antigen-induced bronchoconstriction and mediator release in rat isolated lungs. ( Ottenhof, M; Ufkes, JG; Van Rooij, HH, 1985) |
| "A marked protective action of the corticosteroids prednisolone, hydrocortisone, and dexamethasone has been shown on a hypothetical model of myasthenia gravis, using the rat phrenic nerve-diaphragm preparation treated with hemicholinium-3." | 3.65 | Effect of corticosteroids on the phrenic nerve-diaphragm of preparation treated with hemicholinium. A possible model of myasthenia gravis. ( Leeuwin, RS; Wolters, MJ, 1976) |
| "Prednisolone treated patients and controls became chair bound at the mean age of 169 +/- 9 and 132 +/- 8 months respectively." | 2.72 | Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. ( Ghosh, D; Kumar, A; Mittal, B; Pandey, CM; Pradhan, S; Singh, U; Srivastava, NK, 2006) |
| "Prednisolone treatment did not affect force loss during eccentric contractions or recovery of force following injury." | 1.35 | Effects of prednisolone on skeletal muscle contractility in mdx mice. ( Baltgalvis, KA; Call, JA; Lowe, DA; Nikas, JB, 2009) |
| "Prednisolone did not inhibit either of these responses." | 1.35 | The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo. ( Ishikawa, J; Ohga, K; Shimizu, Y; Takezawa, R; Yamada, T; Yoshino, T, 2008) |
| "Prednisolone treatment increased the frequency of muscle calcification, while RAG2 genotype had no effect." | 1.34 | Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. ( Connolly, AM; Golumbek, PT; Keeling, RM, 2007) |
| "The prednisolone group received prednisolone at a dosage of 5 mg/kg, and the control group received sham saline injections for 5 days." | 1.31 | Detrimental effects of short-term glucocorticoid use on the rat diaphragm. ( Dodd, SL; Eason, JM; Martin, AD; Powers, SK, 2000) |
| " On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs." | 1.31 | Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression. ( Fink, H; Ibebunjo, C; Khiroya, R; Martyn, J; Shin, YS, 2000) |
| "Muscle contraction was easily elicited by percussion, which was visible from the surface and propagated in a rolling manner." | 1.31 | Rippling muscle syndrome preceding malignant lymphoma. ( Ida, M; Kawagoe, S; Kojima, S; Takagi, A; Watanabe, T, 2002) |
| " It is concluded that there was a significant clinical and neurophysiologic response to prednisone at a dosage > or = 0." | 1.29 | Clinical and neurophysiologic response of myopathy and neuropathy in long-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency to oral prednisone. ( Donner, EJ; Hale, DE; Murphy, EG; Tein, I, 1995) |
| "3H-Baclofen was injected i." | 1.27 | [Enhancement of the muscle relaxant action of baclofen by glucocorticoids]. ( Wakayama, K, 1987) |
| "In neostigmine-pretreated animals, however, doses between 12." | 1.26 | Corticosteroids and neuromuscular transmission: electrophysiological investigation of the effects of prednisolone on normal and anticholinesterase-treated neuromuscular junction. ( Birnberger, KL; Dengler, R; Rüdel, R; Warelas, J, 1979) |
| " The glucocorticoid effect on motoneuron outlasts the dosing period, suggesting an underlying alteration in the neuron." | 1.25 | Glucocorticoids and mammalian motor nerve excitability. ( Baker, T; Okamoto, M; Riker, WF, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (54.17) | 18.7374 |
| 1990's | 7 (14.58) | 18.2507 |
| 2000's | 10 (20.83) | 29.6817 |
| 2010's | 5 (10.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akkad, H | 1 |
| Cacciani, N | 1 |
| Llano-Diez, M | 1 |
| Corpeno Kalamgi, R | 1 |
| Tchkonia, T | 1 |
| Kirkland, JL | 1 |
| Larsson, L | 1 |
| Janssen, PM | 1 |
| Murray, JD | 1 |
| Schill, KE | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Rafael-Fortney, JA | 1 |
| Liu, SC | 1 |
| Chu, YH | 1 |
| Kao, CH | 1 |
| Wu, CC | 1 |
| Wang, HW | 1 |
| Dussossoy, E | 1 |
| Bichon, F | 1 |
| Bony, E | 1 |
| Portet, K | 1 |
| Brat, P | 1 |
| Vaillant, F | 1 |
| Michel, A | 1 |
| Poucheret, P | 1 |
| Baltgalvis, KA | 1 |
| Call, JA | 1 |
| Nikas, JB | 1 |
| Lowe, DA | 1 |
| Bauer, R | 1 |
| Blain, A | 1 |
| Greally, E | 1 |
| Lochmüller, H | 1 |
| Bushby, K | 1 |
| MacGowan, GA | 1 |
| Straub, V | 1 |
| Uckert, S | 1 |
| Fuhlenriede, MH | 1 |
| Becker, AJ | 1 |
| Stief, CG | 1 |
| Scheller, F | 1 |
| Knapp, WH | 1 |
| Jonas, U | 1 |
| Pradhan, S | 1 |
| Ghosh, D | 1 |
| Srivastava, NK | 1 |
| Kumar, A | 1 |
| Mittal, B | 1 |
| Pandey, CM | 1 |
| Singh, U | 1 |
| Keeling, RM | 2 |
| Golumbek, PT | 2 |
| Streif, EM | 1 |
| Connolly, AM | 2 |
| Ohga, K | 1 |
| Takezawa, R | 1 |
| Yoshino, T | 1 |
| Yamada, T | 1 |
| Shimizu, Y | 1 |
| Ishikawa, J | 1 |
| Fedin, AN | 1 |
| Kuzubova, NA | 1 |
| Danilov, LN | 1 |
| Lebedeva, ES | 1 |
| Godfraind, T | 1 |
| Burton, J | 1 |
| Edwards, RH | 1 |
| Tein, I | 1 |
| Donner, EJ | 1 |
| Hale, DE | 1 |
| Murphy, EG | 1 |
| Dodd, SL | 2 |
| Powers, SK | 2 |
| Vrabas, IS | 1 |
| Eason, JM | 2 |
| Dekhuijzen, PN | 3 |
| Gayan-Ramirez, G | 2 |
| de Bock, V | 2 |
| Dom, R | 2 |
| Decramer, M | 2 |
| Kiricuta, IC | 1 |
| el-Gammal, S | 1 |
| Altmeyer, P | 1 |
| Beyer, HK | 1 |
| Bisschop, A | 1 |
| Van Balkom, RH | 1 |
| Zhan, WZ | 1 |
| Prakash, YS | 1 |
| Sieck, GC | 1 |
| Martin, AD | 1 |
| Shin, YS | 1 |
| Fink, H | 1 |
| Khiroya, R | 1 |
| Ibebunjo, C | 1 |
| Martyn, J | 1 |
| Takagi, A | 1 |
| Kojima, S | 1 |
| Watanabe, T | 1 |
| Ida, M | 1 |
| Kawagoe, S | 1 |
| Nagai, H | 1 |
| Osuga, K | 1 |
| Koda, A | 1 |
| Lewis, GP | 1 |
| Piper, PJ | 1 |
| Wolters, MJ | 1 |
| Leeuwin, RS | 3 |
| Wolters, EC | 2 |
| Korkach, VI | 1 |
| Hofmann, WW | 1 |
| Dengler, R | 1 |
| Rüdel, R | 1 |
| Warelas, J | 1 |
| Birnberger, KL | 1 |
| Fontaine, J | 1 |
| Famaey, JP | 1 |
| Seaman, I | 1 |
| Reuse, J | 1 |
| Bettini, V | 1 |
| Martino, R | 1 |
| Bizzotto, D | 1 |
| Legrenzi, E | 1 |
| Chamberlain, MA | 1 |
| Keenan, J | 1 |
| Stüttgen, G | 1 |
| Gibson, A | 1 |
| Pollock, D | 1 |
| Spence, JC | 1 |
| Riker, WF | 1 |
| Baker, T | 1 |
| Okamoto, M | 1 |
| Klimova, TT | 1 |
| Sanadze, AG | 1 |
| Skoromets, AA | 1 |
| Khliustova, OV | 1 |
| Nakagawa, T | 1 |
| Uchino, M | 1 |
| Araki, S | 1 |
| Wakayama, K | 1 |
| Ottenhof, M | 1 |
| Ufkes, JG | 1 |
| Van Rooij, HH | 1 |
| Bouyard, P | 1 |
| Balansard, P | 1 |
| Faure, F | 1 |
| Jadot, G | 1 |
| Cueto, C | 1 |
| Moran, NC | 1 |
| Patten, BM | 1 |
| Oliver, KL | 1 |
| Engel, WK | 1 |
| Van Wijngaarden, GK | 1 |
| Lee, P | 1 |
| Baxter, A | 1 |
| Dick, WC | 1 |
| Webb, J | 1 |
| Cseuz, R | 1 |
| Wenger, TL | 1 |
| Kunos, G | 1 |
| Szentiványi, M | 1 |
| Tsurumi, K | 1 |
| Hiramatsu, Y | 1 |
| Nozaki, M | 1 |
| Hayashi, M | 1 |
| Shibuya, T | 1 |
| Fujino, S | 1 |
| Yorozuya, S | 1 |
| Izumi, T | 1 |
| Tanaka, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)[NCT05185622] | Phase 2 | 54 participants (Anticipated) | Interventional | 2022-03-21 | Recruiting | ||
| A Phase II Pilot Trial of Vamorolone vs. Placebo for the Treatment of Becker Muscular Dystrophy[NCT05166109] | Phase 2 | 39 participants (Anticipated) | Interventional | 2022-07-07 | Recruiting | ||
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
2 reviews available for prednisolone and Muscle Contraction
| Article | Year |
|---|---|
New techniques for studying human muscle function, metabolism, and fatigue.
Topics: Biopsy, Needle; Electric Stimulation; Electromyography; Energy Metabolism; Humans; Magnetic Resonanc | 1984 |
[Effect of glucocorticoids on functional and metabolic processes in the muscles (review of the literature)].
Topics: Adenosine Triphosphate; Adrenalectomy; Adrenocorticotropic Hormone; Animals; Cortisone; Glucocortico | 1976 |
3 trials available for prednisolone and Muscle Contraction
| Article | Year |
|---|---|
Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation.
Topics: Accidental Falls; Anti-Inflammatory Agents; Child; Female; Gait Disorders, Neurologic; Humans; Locom | 2006 |
The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis.
Topics: Adrenal Glands; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relation | 1976 |
An assessment of grip strength measurement in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biomechanical Phenomena; Circadian Rhythm; Clinical Trials as Topic; Function | 1974 |
43 other studies available for prednisolone and Muscle Contraction
| Article | Year |
|---|---|
Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.
Topics: Animals; Anti-Inflammatory Agents; Contractile Proteins; Critical Illness; Cytokines; Disease Models | 2019 |
Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.
Topics: Animals; Anti-Inflammatory Agents; Contractile Proteins; Critical Illness; Cytokines; Disease Models | 2019 |
Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.
Topics: Animals; Anti-Inflammatory Agents; Contractile Proteins; Critical Illness; Cytokines; Disease Models | 2019 |
Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model.
Topics: Animals; Anti-Inflammatory Agents; Contractile Proteins; Critical Illness; Cytokines; Disease Models | 2019 |
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Diuretics; Dystrophin; Female; Gene Expression; | 2014 |
Steroids and antihistamines synergize to inhibit rat's airway smooth muscle contractility.
Topics: Animals; Cetirizine; Cholinergic Agents; Disease Models, Animal; Drug Synergism; Electric Stimulatio | 2015 |
Pulmonary anti-inflammatory effects and spasmolytic properties of Costa Rican noni juice (Morinda citrifolia L.).
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antioxidants; Calcium Channel Blockers; Cal | 2016 |
Effects of prednisolone on skeletal muscle contractility in mdx mice.
Topics: Animals; Anti-Inflammatory Agents; Body Mass Index; Disease Models, Animal; Dose-Response Relationsh | 2009 |
Attenuation of adverse cardiac effects in prednisolone-treated delta-sarcoglycan-deficient mice by mineralocorticoid-receptor-antagonism.
Topics: Administration, Oral; Animals; Body Weight; Fibrosis; Glucocorticoids; Heart; Heart Diseases; Hemody | 2010 |
Is there an inhibitory role of cortisol in the mechanism of male sexual arousal and penile erection?
Topics: Adult; Arousal; Endothelin-1; Glucocorticoids; Humans; Hydrocortisone; Male; Muscle Contraction; Mus | 2003 |
Weekly oral prednisolone improves survival and strength in male mdx mice.
Topics: Administration, Oral; Age Factors; Animals; Anti-Inflammatory Agents; Body Weight; Disease Models, A | 2007 |
Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout.
Topics: Age Factors; Analysis of Variance; Animals; Creatine Kinase; DNA-Binding Proteins; Female; Forelimb; | 2007 |
The suppressive effects of YM-58483/BTP-2, a store-operated Ca2+ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Blood Cells; Bronchial Hyperreactivity; Bronchoconstric | 2008 |
[Functional disturbances in the nervous structures of the respiratory tract in rats following nitrogen dioxide inhalation].
Topics: Anesthetics, Local; Animals; Bronchi; Glucocorticoids; In Vitro Techniques; Male; Muscle Contraction | 2007 |
Inhibition by prednisolon-bisguanylhydrazone of desensitization and of potassium loss produced by acetylcholine in intestinal smooth muscle.
Topics: Acetylcholine; Animals; Guinea Pigs; Hydrazines; Ileum; Muscle Contraction; Muscle, Smooth; Potassiu | 1967 |
Clinical and neurophysiologic response of myopathy and neuropathy in long-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency to oral prednisone.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Administration, Oral; Child; Dose-Response Relationship, Drug; Fol | 1995 |
Interaction of glucocorticoids and activity patterns affect muscle function.
Topics: Animals; Body Weight; Diaphragm; Female; Hindlimb; Muscle Contraction; Muscle Fatigue; Muscle Fibers | 1995 |
Triamcinolone and prednisolone affect contractile properties and histopathology of rat diaphragm differently.
Topics: Animals; Body Weight; Diaphragm; Fatigue; Male; Muscle Contraction; Prednisolone; Rats; Rats, Wistar | 1993 |
Altered muscle metabolism in pustular psoriasis (Zumbusch type): demonstration by 31P magnetic resonance spectroscopy.
Topics: Adenosine Triphosphate; Adult; Etretinate; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Sp | 1993 |
Recovery of corticosteroid-induced changes in contractile properties and morphology of rat diaphragm.
Topics: Animals; Body Weight; Diaphragm; Glucocorticoids; In Vitro Techniques; Male; Muscle Contraction; Org | 1996 |
Corticosteroid effects on isotonic contractile properties of rat diaphragm muscle.
Topics: Adrenal Cortex Hormones; Animals; Diaphragm; Glucocorticoids; Isotonic Contraction; Kinetics; Male; | 1997 |
Detrimental effects of short-term glucocorticoid use on the rat diaphragm.
Topics: Animals; Body Weight; Diaphragm; Female; Glucocorticoids; Muscle Contraction; Muscular Atrophy; Orga | 2000 |
Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.
Topics: Animals; Dose-Response Relationship, Drug; Electric Stimulation; Glucocorticoids; Hindlimb; Male; Mu | 2000 |
Rippling muscle syndrome preceding malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Electromyography; Hyp | 2002 |
Inhibition of hypersensitivity reactions by soluble derivatives of baicalein.
Topics: Aminophylline; Anaphylaxis; Animals; Antigens; Arthus Reaction; Asthma; Chlorpheniramine; Female; Fl | 1975 |
Inhibition of release of prostaglandins as an explanation of some of the actions of anti-inflammatory corticosteroids.
Topics: Adipose Tissue; Adrenocorticotropic Hormone; Animals; Betamethasone; Biological Transport, Active; B | 1975 |
Effect of corticosteroids on the phrenic nerve-diaphragm of preparation treated with hemicholinium. A possible model of myasthenia gravis.
Topics: Adrenal Cortex Hormones; Animals; Dexamethasone; Diaphragm; Female; Hemicholinium 3; Hydrocortisone; | 1976 |
Effect of corticosteroids on sciatic nerve-tibialis anterior muscle of rats treated with hemicholinium-3. An experimental approach to a possible mechanism of action of corticosteroids in myasthenia gravis.
Topics: Animals; Betamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glucocorti | 1977 |
Antimyasthenic action of corticosteroids.
Topics: Action Potentials; Animals; Curare; Diaphragm; Hemicholinium 3; In Vitro Techniques; Magnesium; Male | 1977 |
Corticosteroids and neuromuscular transmission: electrophysiological investigation of the effects of prednisolone on normal and anticholinesterase-treated neuromuscular junction.
Topics: Animals; Dose-Response Relationship, Drug; Drug Interactions; In Vitro Techniques; Male; Muscle Cont | 1979 |
Inhibition of caerulein and physalaemin-induced contractions of guinea-pig isolated ileum by non-steroidal antiinflammatory drugs and various steroids and their reversal by prostaglandin E1.
Topics: Animals; Anti-Inflammatory Agents; Betamethasone; Ceruletide; Drug Antagonism; Female; Gonadal Stero | 1978 |
Influence of prednisolone on the response of coronary artery, treated with propranolol, to noradrenaline.
Topics: Animals; Arteries; Cattle; Coronary Vessels; Drug Synergism; Muscle Contraction; Muscle, Smooth, Vas | 1978 |
Vasoconstriction in response to corticosteroids observed in human lips.
Topics: Adrenal Cortex Hormones; Capillaries; Drug Interactions; Fluocinolone Acetonide; Humans; Infrared Ra | 1976 |
The effects of corticosteroids on the responses of the anococcygeus and gastrocnemius muscles to nerve stimulation in the pithed rat [proceedings].
Topics: Adrenal Cortex Hormones; Animals; Corticosterone; Electric Stimulation; Male; Muscle Contraction; Mu | 1976 |
Glucocorticoids and mammalian motor nerve excitability.
Topics: Animals; Cats; Chlorides; Desoxycorticosterone; Dose-Response Relationship, Drug; Evoked Potentials; | 1975 |
[Possibilities of using enterosorption in the treatment of myasthenia gravis].
Topics: Adolescent; Adult; Azathioprine; Charcoal; Child; Combined Modality Therapy; Enterosorption; Eye Mov | 1991 |
[A case of chronic inflammatory demyelinating polyradiculoneuropathy with diurnal fluctuation of clinical symptoms during administration of prednisolone].
Topics: Adult; Betamethasone; Chronic Disease; Circadian Rhythm; Humans; Male; Median Nerve; Muscle Contract | 1988 |
[Enhancement of the muscle relaxant action of baclofen by glucocorticoids].
Topics: Animals; Baclofen; Drug Synergism; Hydrocortisone; Muscle Contraction; Muscle Relaxants, Central; Mu | 1987 |
The effect of prednisolone and ketotifen on the antigen-induced bronchoconstriction and mediator release in rat isolated lungs.
Topics: Anaphylaxis; Animals; Bronchi; Female; Histamine; In Vitro Techniques; Ketotifen; Lung; Muscle Contr | 1985 |
[Pharmacological study of an antibiotic derived from sterane: sodium fusidate].
Topics: Animals; Anti-Bacterial Agents; Blood Pressure; Female; Fusidic Acid; Heart; Male; Muscle Contractio | 1970 |
The circulatory effects of catecholamines and ouabain in glucocorticoid-deficient animals.
Topics: 17-Hydroxycorticosteroids; Adrenocorticotropic Hormone; Animals; Blood Pressure; Blood Volume; Defic | 1968 |
Adverse interaction between steroid hormones and anticholinesterase drugs.
Topics: Action Potentials; Animals; Anura; Cholinesterase Inhibitors; Dexamethasone; Drug Interactions; Edro | 1974 |
The effect of prednisolone on the rat phrenic nerve-diaphragm preparation treated with hemicholinium.
Topics: Animals; Diaphragm; Dose-Response Relationship, Drug; Electric Stimulation; Female; Hemicholinium 3; | 1974 |
Changes of adrenergic reaction pattern in experimental diabetes mellitus.
Topics: Animals; Aorta; Cold Temperature; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; | 1973 |
[Anti-inflammatory action of N-(2,6-dichlorophenyl)-o-aminophenylacetic acid, its sodium salt, N-(2,6-dichlorophenyl)-anthranilic acid and its sodium salt. 1. On acute inflammation].
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Capillary Permeability; Edema; Electrolytes; Eryth | 1973 |
Anti-ouabain action of steroid hormones on twitch and potassium contracture in heart ventricle strip of frog.
Topics: Aldosterone; Animals; Anura; Corticosterone; Desoxycorticosterone; Dexamethasone; Estradiol; Glucoco | 1969 |